Synthetic Biologics Stock Price - SYN

0.007 (1.40%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Synthetic Biologics Inc SYN AMEX Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.007 1.4% 0.507 0.4908 0.5248 0.513 0.50 13:49:08
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
233 73,985 $ 0.5018722 $ 37,131 294,195 0.365 - 0.8499
Last Trade Time Type Quantity Stock Price Currency
13:51:51 48 $ 0.5002 USD

Synthetic Biologics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 8.52M 16.81M $ -13.37M -4.07 - 11.24M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
74.73k $ - 0.00% 5.00 33.10%

more financials information »

Synthetic Biologics News

Loading Messages....

Latest SYN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SYN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.530.5460.450.5224201161,915-0.023-4.34%
1 Month0.5510.62940.450.5610883186,796-0.044-7.99%
3 Months0.39180.790.3890.5162545235,3770.115229.4%
6 Months0.460.790.3650.4929428148,4600.04710.22%
1 Year0.65060.84990.3650.5823701177,654-0.1436-22.07%
3 Years28.7036.750.36515.16677,325-28.19-98.23%
5 Years74.20151.200.36546.43828,253-73.69-99.32%

Synthetic Biologics Description

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.